Top 50 Life Science Startup Investors in China (May 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Sequoia Capital China
VC Fund
|
5 | China, United States, Australia | Series A, Series B, Series C | Health Care, Biotechnology, Artificial Intelligence | $4M–$200M |
|
Hillhouse Capital Group
VC Fund
|
5 | China, United States, India | Series B, Series A, Series C | Biotechnology, Health Care, Software | $1.4M–$310M |
|
EFung Capital
VC Fund
|
4 | China, United States, India | Series A, Series B, Series C | Biotechnology, Health Care, Pharmaceutical | $1.4M–$84M |
|
Huagai Capital
VC Fund
|
4 | China, United States, Hong Kong | Series A, Series B, Angel | Health Care, Biotechnology, Medical | $412k–$90M |
|
Prox Ventures
VC Fund
|
4 | China, United States, United Kingdom | Seed, Series A | Medical, Biotechnology, Health Care | |
|
Entrepreneurship Relay Group
VC Fund
|
3 | China | Series A, Angel, Series C | Medical, Life Science, Biotechnology | |
|
Qiming Venture Partners
VC Fund
|
3 | China, United States, Hong Kong | Series B, Series A, Series C | Health Care, Medical, Biotechnology | $4.1M–$148M |
|
Legend Capital
VC Fund
|
3 | China, United States, South Korea | Series B, Series A, Series C | Health Care, Biotechnology, Medical | $2.7M–$200M |
|
BioVenture
VC Fund
|
3 | China, United States, Taiwan | Series A, Series B, Series C | Health Care, Medical, Biotechnology | $2.7M–$58M |
|
Eight Roads Ventures
VC Fund
|
2 | United States, China, India | Series B, Series A, Series C | Software, Health Care, Information Technology | $5.4M–$100M |
|
Loyal Valley Capital
VC Fund
|
2 | China, United States, Hong Kong | Series C, Series B, Series A | Biotechnology, Health Care, Pharmaceutical | $14M–$279M |
|
Bits x Bites
VC Fund
|
2 | China, Israel, Singapore | Series A, Seed, Series B | Biotechnology, Food and Beverage, Food Processing | $4k–$38M |
|
Highlight Capital
VC Fund
|
2 | China, United States, Portugal | Series A, Series B, Series C | Health Care, Biotechnology, Medical | $2.7M–$200M |
|
Oriental Fortune Capital
VC Fund
|
2 | China, United States | Series A, Series B, Seed | Software, Information Technology, E-Commerce | $412k–$100M |
|
ULTIMA
VC Fund
|
2 | China | Angel, Series A | Hardware, Software, Agriculture | |
|
CentreGold Capital
VC Fund
|
2 | United States, China, Canada | Seed, Series A, Angel | Internet, Medical Device, Artificial Intelligence | $549k–$3M |
|
BOHE Angel Fund
VC Fund
|
2 | China | Angel, Seed, Series A | Health Care, Medical, Biotechnology | |
|
Orient Securities Capital Investment
VC Fund
|
2 | China | Series A, Series D, Series C | Health Care, Manufacturing, Software | $1.4M–$69M |
|
Lucion
VC Fund
|
2 | China | Series A, Seed, Series B | Biotechnology, Medical, Manufacturing | $1.4M–$522M |
|
Sherpa Venture Capital
VC Fund
|
2 | China, United States, Kenya | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $6.9M–$151M |
|
Lilly Asia Ventures
VC Fund
|
2 | China, United States, Hong Kong | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $11M–$275M |
|
Med-Fine Capital
VC Fund
|
2 | China, United States | Series A, Series B, Seed | Health Care, Biotechnology, Medical | $2.7M–$50M |
|
Green Pine Capital Partners
VC Fund
|
2 | China, United States, Canada | Series A, Angel, Series B | Artificial Intelligence, Manufacturing, Software | $412k–$150M |
|
CD Capital
VC Fund
|
2 | China, United States | Series A, Series B, Angel | Health Care, Biotechnology, Medical Device | $412k–$34M |
|
ASBV
VC Fund
|
2 | China | Series A, Seed, Angel | Health Care, Medical, Biotechnology | $412k–$30M |
|
WuXi AppTec
VC Fund
|
2 | United States, China, Israel | Series A, Series B, Series C | Biotechnology, Pharmaceutical, Health Care | $5.9M–$100M |
|
Huimei Capital
VC Fund
|
2 | China, United States, Japan | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $10M–$220M |
|
MiraclePlus
VC Fund
|
2 | China, United States, Singapore | Seed, Angel, Pre-Seed | Artificial Intelligence, Software, Information Technology | $200k–$3M |
|
Step Fund
VC Fund
|
1 | China | Seed, Series B | Biotechnology, Software, Electronics | |
|
Haitang Fund
VC Fund
|
1 | China | Series A | Life Science, Biotechnology, Advanced Materials | |
|
Ennovation Ventures
VC Fund
|
1 | China | Seed | ||
|
Saizhi Bole
VC Fund
|
1 | China | Series B | Software, Manufacturing, Data and Analytics | |
|
Wanwu Capital
VC Fund
|
1 | China | Series A, Seed | Artificial Intelligence, Agriculture, SaaS | |
|
Qingdao Qingchi Venture Capital
VC Fund
|
1 | China | Series A | Biotechnology, Science and Engineering | |
|
Q Ventures
VC Fund
|
1 | China | Series A | Biotechnology, Science and Engineering | |
|
SDIC Venture Capital
VC Fund
|
1 | China, United States, Hong Kong | Series B, Series A, Series C | Manufacturing, Biotechnology, Health Care | $2.7M–$275M |
|
Hubei Tianchi Enterprise Management
VC Fund
|
1 | China | Series A | Medical, Health Care, Life Science | |
|
Dynamic Balance Capital
VC Fund
|
1 | China | Series A, Angel, Seed | Health Care, Manufacturing, Biotechnology | |
|
Qingdao Holdings International
VC Fund
|
1 | China | Seed | AgTech, Genetics, Life Science | |
|
Haoping Investment
VC Fund
|
1 | China | Seed | Medical, Life Science, Biotechnology | |
|
Zhongke Weilan
VC Fund
|
1 | ||||
|
Kunlun Capital
VC Fund
|
1 | China | Seed, Series A, Series B | Biotechnology, Medical, Genetics | $20M–$27M |
|
China Medical System Holdings Limited
VC Fund
|
1 | China, United Kingdom | Seed | Biotechnology, Medical, Health Care | |
|
Sunz Fund
VC Fund
|
1 | China | Series A, Series B, Seed | Medical, Health Care, Biotechnology | $1.4M–$2.7M |
|
Anhui High-tech Industry Investment
VC Fund
|
1 | China | Angel | Medical, Health Care, Life Science | |
|
Qiji Zhiguang Fund
VC Fund
|
1 | China | Angel | Life Science, Biotechnology | |
|
Tsing-Yuan Capital
VC Fund
|
1 | China, United States | Series A, Angel, Series B | Manufacturing, Health Care, E-Commerce | $412k–$14M |
|
Country Garden Venture Capital
VC Fund
|
1 | China, France, Germany | Series A, Seed, Series B | Manufacturing, Biotechnology, Hardware | $1.4M–$1.5B |
|
Starlight Capital
VC Fund
|
1 | China | Series A | Software, Agriculture, Life Science | |
|
Cathay Biotech
VC Fund
|
1 | China | Seed | Medical, Life Science, Biotechnology | |
| Access all 319 investors in China Life Science startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
We help founders build enduring companies.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Artificial Intelligence
- Stage:Series A, Series B, Series C
- Geography: China, United States, Australia
Investor stats
- Total investments: 643
- Round size: Series A $4M–$90M; Series B $11M–$172M; Series C $25M–$200M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- FUE Bioscience — FUE Bioscience is a medical robot R&D business that specializes in microsurgery above the head and neck. It continues to develop a product matrix of fully intelligent, high-precision, and anthropomorphic surgical robots based on the platform of macro-micro-controlled humanoid dual-arm robots.
- Life Wilderness — Life Wilderness reimagines human-computer interaction and is linked to the transportation and travel industries.
- Xintu Heterogeneous — Xintu Heterogeneous offers data storage solutions for heterogeneous computing.
Hillhouse Capital Group is an investment management firm that invests with a long-term time horizon. Hillhouse owns companies across equity stages, spanning the range from new start-ups to the world’s most established public companies. It may invest in a company as a start-up and continue to hold it in the portfolio as a public equity investment.This stage-agnostic investment style allows them to focus on multi-year results, rather than on quarterly earnings.Hillhouse Capital Group invests globally, with a particular focus on Asia. Independent, proprietary research lies at the heart of our investment process. Our team members are sector experts in consumer, Internet, media, and healthcare. Hillhouse Capital Group was founded in 2005 and is based in Beijing, China.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series B, Series A, Series C
- Geography: China, United States, India
Investor stats
- Total investments: 312
- Round size: Series A $1.4M–$120M; Series B $14M–$230M; Series C $14M–$310M
- Lead/follow: 38% lead, 62% follow
- Last fund: May invest from a new fund soon — last raise in 2018
Portfolio highlights
- Immorna — Immorna specializes in the production of RNA-based therapeutics.
- Xingmai Innovation — Xingmai Innovation creates, develops, and sells intelligent swimming pool cleaning robots.
- Deep Vision Intelligence — Deep Vision Intelligence is a developer of embedded machine vision products.
Shenzhen EFUNG Investment Management Enterprise L. P. is one of China's earliest institutions investing in professional biomedical industries. Their strong research team and great investment returns made us won 'The Most Pioneering VC Institution” 'The Most Dynamic Pharmaceutical VC Institution in China' and 'The Top Ten VCInstitutions in Shenzhen'. With this influence, EFUNG has drawn a lot of attention from the medical and life science industry. And it is interviewed by Nature, which is the most authoritative science magazine in the world. Over a decade of years, they have been focusing on the medical and health industry, especially the VC and PE investment business of novel drugs and high-end medical devices. The mission of EFUNG is to drive the industrialization of medical researches by capital and to gain rich returns to investors. EFUNG has deeply screened and invested in more than 20 domestic and international premium enterprises, such as Chipscreen Biosciences, Frontier Biotechnologies, Ascentage Pharma, Lifotronic, Aridis Pharmaceuticals, and Centrexion.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series A, Series B, Series C
- Geography: China, United States, India
Investor stats
- Total investments: 42
- Round size: Series A $1.4M–$76M; Series B $15M–$84M; Series C $14M–$69M
- Lead/follow: 26% lead, 74% follow
Portfolio highlights
- Turno — Turno Finance makes owning EV very affordable. Turno Club is a community around commercial EVs. Turno Battery Future is our solution to keeping batteries on the road for longer.
- IASO Biotherapeutics — IASO Biotherapeutics (IASO BIO) is a Nanjing-based biopharmaceutical company focused on the discovery, development and commercialization of cell therapies in the field of oncology.
- Huayuan Regenerative Medicine — Huayuan Regenerative Medicine is a developer of implantable biological artificial organs.
Huagai Capital is a private equity investment firm that invests in start-up or growth companies in the areas of healthcare, TMT, and culture.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Angel
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 110
- Round size: Angel $412k–$1.3M; Series A $1.4M–$60M; Series B $3.5M–$90M
- Lead/follow: 44% lead, 56% follow
- Last fund: May invest from a new fund soon — raised $430M in 2018
Portfolio highlights
- Leo Summit — Leo Summit is positioned as a provider of life science laboratory automation solutions. It provides reliable and flexible solutions for the biomedical industry, driven by the demand for automated intelligent technology in clinical medicine and drug R&D industries, and relies on artificial intelligence and motion control technology. Providesystematic intelligent products and solutions for R&D firms, AI pharmaceuticals, and CRO firms in the fields of new medications, synthetic biology, and single-cell sequencing.
- Leaf Biotech — Leaf Biotech is a research and development, production and sales of green chemical-related materials and series intermediates. The business produces biomass resources. The focus of the research and development is the bio-based polyester material PEF and important intermediates, as well as the creation of green drugs and intermediates for healthcareproducts.
- Dingzhi Biotech — Dingzhi Biotech specialized in immunology and animal vaccine development. It focuses on innovative and large varieties in the research of covers poultry, livestock, and pets.
Proxima Ventures focuses in the healthcare industry, supporting outstanding enterprises with innovative technologies or service models that have tremendous potential.They manage multiple funds in RMB and US dollar, covering from seed to growth stages. Their team members with multidisciplinary backgrounds and resourceful networks, have many yearsof remarkable venture capital experience and achievements. They believe that active and effective collaboration with entrepreneurs will make substantial economic returns while bring meaningful improvements in public health.
Show more...Investment focus
- Industry: Medical, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: China, United States, United Kingdom
Investor stats
- Total investments: 46
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- VerImmune — Located in Baltimore, Maryland, VerImmune is an Immuno-Oncology company developing a first-in-class cancer therapy known as Anti-tumor Immune Redirection. This strategy utilizes a proprietary tumor-specific, tumor type agnostic, virus-inspired platform termed Anti-tumor Immune Redirection Virus-inspired Particles (AIR-ViPs) that redirectspre-existing pathogenic or childhood vaccine immune memory towards tumors.
- VacV Biotech — VacV Biotherapeutics develops an oncolytic virus platform based on the vaccinia virus. The platform genetically modifies the oncolytic virus, which improves its specificity to tumors, reduces neurotoxicity, enhances the therapeutic effect, and greatly increases the production of extracellular enveloped virus (EEV). It has higher safety andefficiency and can be administered by intravenous injection.
- HROCT LITT Medtech — HROCT LITT Medtech has developed the unique SNP(Smart Needle Probe) needle imaging, assembled as a catheter, which OD is smaller than 1/5 of the traditional invasive OCT catheter, while the depth and resolution are all multiple times of the traditional invasive OCT catheter, achieving 1um level to supply the histopathology needed microimaging.The fiber could be compatible with different kinds of biopsy needles to access the targets, and also could be coupled with a specific laser to achieve OCT situ diagnosis and laser ablation. Its technology provides revolutionary solutions to neurosurgery, interventional pulmonology, neurovascular, nephropathy, mammary gland, cardiac, GI, and other fields.
Entrepreneurship Relay Group manages a fund of more than 4 billion yuan, directly or indirectly.
Show more...Investment focus
- Industry: Medical, Life Science, Biotechnology
- Stage:Series A, Angel, Series C
- Geography: China
Investor stats
- Total investments: 6
- Lead/follow: 17% lead, 83% follow
Portfolio highlights
- ZStack — ZStack Cloud Platform has served more than 1,000 enterprise users and established ecological and channel partnerships with more than 200 cloud vendors, covering government, finance, education, internet, energy, manufacturing and many other industries.
- Bangqi Biological — Bangqi Biological is a biotechnology company that focuses on the research and development, production, registration, quality, supply chain and sales of instruments and reagents for autoimmunity & allergy diagnosis.
- Shanghai Bioprofile — Shanghai Bioprofile is a metabonomics technology service provider.
Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston and the San Francisco Bay Area.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.4 billion in capital raised. Since our establishment, we have investedin outstanding companies in the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 480 fast-growing and innovative companies. Over 180 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange or Shenzhen Stock Exchange, or through M&A or by other means. There are also over 70 portfolio companies that have achieved unicorn status.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series B, Series A, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 487
- Round size: Series A $4.1M–$48M; Series B $10M–$100M; Series C $16M–$148M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Atantares — We are a development stage startup enabling the next generation of precision medicine by fusing biochip and AI technologies.
- Saints Sages Medical — Saints Sages Medical is engaged in the production and sales of minimally invasive surgical medical devices. They have several energy device products that are widely used in minimally invasive surgery, hepatobiliary surgery, gynecology, urology, thoracic surgery, and other departments. Saints Sages closely monitors clinical needs and develops moreinnovative minimally invasive surgical devices to serve global patients, relying on a professional research and development team and years of the clinical transformation experience.
- Epigenic Therapeutics — Epigenic Therapeutics is a biotech firm that offers gene editing therapy.
Legend Capital, a subsidiary of Legend Holdings Ltd., started its vintage year in April, 2001 with a mission to become a top-notch and the most respected venture capital investment manager in China.Managing up to US$700 million across four funds, Legend Capital focuses on driving high-growth ventures with operations substantially based in Chinaor on markets related to China.Legend Capital mainly invests in early stage IT companies, specifically, in sectors of network applications and services, outsourcing and professional services, Infrastructure (IC design/key components), and mid-market growth stage companies in the fields of consumer goods, clean technology, health care, equipment manufacturing and modern services.Among over 60 portfolio companies are Joyo.com (acquired by Amazon.com), SinoCom (0299.HK), Solarfun Power (Nasdaq: SOLF), Spreadtrum Communications (Nasdaq: SPRD), China Sunshine Paper (2002.HK), and VanceInfo (NYSE:VIT), Eyang (0117.HK), etc.As an active investor, Legend Capital provides its portfolio companies extensive business resources and tailored services to assist with business development, company image building, and other critical company building activities on Chinese market so as to add value and maximize returns. Legend Capital is proud and thankful that it has the opportunity to blaze a trail with its innovative practice for China's venture capital industry.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series A, Series C
- Geography: China, United States, South Korea
Investor stats
- Total investments: 277
- Round size: Series A $2.7M–$50M; Series B $11M–$110M; Series C $15M–$200M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely still investing — fund raised in 2021
Portfolio highlights
- HC Scientific — HC Scientific is a high-tech enterprise integrating research, development, production and sales of a new biomedical system
- Saige Research — Saige Research specializes in artificial intelligence solutions for industrial inspection and quality control. The company provides a deep learning vision inspection platform optimized for the manufacturing industry to solve inspectors' difficulties and increase work efficiency; its technology provides power detection, speed detection, wideversatility, and development convenience.
- Ligatech Bioscience — Ligatech Bioscience is an intrusive consumables developer specializing in the development and manufacture of medical devices for the field of sports medicine, as well as the development and production of biomedical materials and products. A production line for artificial ligaments and artificial ligament fixation systems has been established. Andprovide users with relevant technical advice and technical services.
Suzhou Industrial Park Bioventure Investment Management Limited (Bioventure) was established in September 2013. Bioventure its first element of the new bio-industry funds 540 million yuan fund size. Bioventure specialize in the field of life sciences in the early stages of the venture capital investments as having high strength and growth, greaterdevelopment space, excellent management team, biotechnology, drug discovery, medical devices and healthcare services companies, and provide capital, management , operation and other aspects of post-investment support and services.Bioventure brought together senior investment professionals team with bio-pharmaceutical industry investment experience, strong fund management, entrepreneurship and venture capital and operating experience in business, have a deep understanding of the domestic and foreign markets, capable of its forward-looking international perspective and extensive The industry has the potential resources to help innovative companies grow rapidly and gain greater success, while giving fund investors bring considerable returns.Suzhou Industrial Park, the core investor BioBay has the country's best medical and pharmaceutical incubator function, use the platform, the project team has great resources and industrial service advantages, Yuan-sheng venture has successfully invested in 20 projects have been cast projects in their own development and follow-up financing, has made outstanding achievements in the industry for all to see, and won the Venture's trust and praise.By focusing and extensive industry resources, Bioventure determined to become one of China's most successful medical and pharmaceutical venture fund. Bioventure expectations and in the medical and pharmaceutical industry where there joint venture development cooperation.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: China, United States, Taiwan
Investor stats
- Total investments: 76
- Round size: Series A $2.7M–$41M; Series B $2.7M–$55M; Series C $14M–$58M
- Lead/follow: 49% lead, 51% follow
- Last fund: May invest from a new fund soon — last raise in 2016
Portfolio highlights
- Xiguang Bio — Xiguang Bio focuses on the production of diagnostic reagents and provides chemiluminescent raw materials and overall system technology solutions.
- Jiamuyao Medical — Jiamuyao Medical specialized in developing an energy platform for the comprehensive treatment of complex intravascular lesions.
- Panomic Biomedical Technology — Suzhou Panomic Biomedical Technology Co., Ltd. (BioNovoGene) was founded in Suzhou Industrial Park Bio-Nano Park in 2013. It is a leading high-tech enterprise focusing on metabolomics in China. Since its establishment, it has established a complete metabolomics detection and analysis platform - PanomicTM / Bionovogene, including metabolitepreprocessing platform, high-resolution mass spectrometry analysis platform, and metabolomics data analysis with independent intellectual property rights The system has perfect biomarker discovery capabilities and clinical application capabilities. The company's scientific research team has a rich background, covering biochemistry, bioinformatics, epidemiology and biostatistics, computer science, etc., and has a consultant team composed of top scientists and clinicians.
Eight Roads has a 50+ year history of investing and partners with game-changing technology and healthcare companies, supporting them as they scale to become global leaders.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Series B, Series A, Series C
- Geography: United States, China, India
Investor stats
- Total investments: 309
- Round size: Series A $5.4M–$62M; Series B $7.3M–$100M; Series C $13M–$100M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely still investing — raised $350M in 2022
Portfolio highlights
- Ketai Bio — Ketai Bio is a synthetic biology company dedicated to the R&D, production and sales of high value-added bio-based products.
- New Vision Medical — New Vision Medical is an IT infrastructure service provider that offers clinical trial-related digital platforms and services.
- Tenpoint Therapeutics — Tenpoint Therapeutics is a biotechnology company pursuing vision-restoring engineered cell-based therapeutics.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Loyal Valley Capital (LVC) is a thematic, research-driven private equity firm with strong entrepreneurial culture that invests in middle market companies positioned to benefit from the secular industry transformations in China. With over US$1.6 billion of assets under management, LVC mainly focuses on the following segments: Consumer (TMT,Internet, and Education), Healthcare, and Advanced Manufacturing. Our investment process is characterized by in-depth top-down and bottom-up fundamental research to uncover secular themes and utilize extensive industry mapping to deploy capital in a high conviction and disciplined approach. We pride ourselves as a trusted influential shareholder relentlessly focused on active value creation and accelerating growth via strategic initiatives through our extensive network of business leaders in China. LVC manages capital on behalf of international institutional investors such as sovereign wealth funds, funds of funds, private banks, and family offices, as well as elite entrepreneurs and founders of China’s Fortune 500 enterprises.LVC was founded in 2015 by Andy Lin, an experienced investor and accomplished entrepreneur. He is the founder of China Universal Asset Management (“CUAM”), one of China’s largest equity investor and asset manager with over US$100B in AUM, known for its industry leading research and award-winning investment records.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series C, Series B, Series A
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 76
- Round size: Series A $14M–$279M; Series B $25M–$137M; Series C $33M–$220M
- Lead/follow: 46% lead, 54% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Chabaidao — Chabaidao is a tea drink brand that aims to create surprises through product development and trendy gameplay.
- Jinyuansheng — Jinyuansheng is mainly engaged in the development, smelting and deep processing of new energy key metal mineral resources.
- Medilink Therapeutics — MediLink Therapeutics has established its R&D center in Suzhou, China. The company focuses on developing next generation drug conjugates, and aims to serve the vast unmet medical needs in China, and create global value through conducting multicenter clinical trials and cross-border collaborations.
Bits x Bites is a food tech VC that invests in early-stage startups tackling global food system challenges. It targets companies innovating across the food supply chain, from farming, production, distribution, and logistics, to consumer goods and food services.
Show more...Investment focus
- Industry: Biotechnology, Food and Beverage, Food Processing
- Stage:Series A, Seed, Series B
- Geography: China, Israel, Singapore
Investor stats
- Total investments: 27
- Round size: Seed $4k–$20M; Series A $412k–$38M
- Lead/follow: 11% lead, 89% follow
- Last fund: May invest from a new fund soon — last raise in 2020
Portfolio highlights
- Ketai Bio — Ketai Bio is a synthetic biology company dedicated to the R&D, production and sales of high value-added bio-based products.
- Mojia Bioscience — Mojia Bioscience is a biotechnology company.
- Changjin Biotechnology — Changjin Biotechnology engages in the research, development, and industrialization of microbial synthetic proteins.
They are an investment firm dedicated to support healthcare companies to generate robust and sustained growth prospect in China and to partner with entrepreneurs with dedication and the highest standard.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, Portugal
Investor stats
- Total investments: 92
- Round size: Series A $2.7M–$26M; Series B $2.7M–$70M; Series C $16M–$200M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely still investing — fund raised in 2021
Portfolio highlights
- Etana — PT Etana Biotechnologies Indonesia (Etana) is an emerging producer of high-quality, affordable and innovative biopharmaceuticals to treat a range of metabolic, autoimmune and other major life-threatening diseases, including cancer. Nathan Tirtana. Legend Capital. UOB Venture Management. Innovent Bio
- Hongyixin — Hongyixin is an automotive electronic chip developer.
- Acchrom Tech — Huapu Instrument (Beijing) Technology Co., Ltd. is committed to building Huapu into a well-known national brand in the field of chromatography, and is an enterprise that provides the overall solution of "product + technical service" in the field of chromatography. The company formulates differentiated marketing strategies, builds anationwide marketing team centered on key provinces, and builds a professional and efficient marketing network.
Shenzhen Oriental Fortune Capital Co Ltd. is a venture capital firm specializing investment in early venture, mid venture, late venture, emerging growth, Pre-IPO, mature, growth capital stage, mezzanine and new third board investments. The firm typically invests in financial services, telecommunication, new energy, consumer goods, medical treatmentand healthcare, life sciences, internet plus healthy lifestyle industry, logistics, energy technology, information technology, mobile innovation, media, movies and television, culture, pharmaceutical, biological medicine, renewable energy, retail, environmental protection business, consumption, new materials, new agriculture, advanced manufacturing, equipment manufacturing, culture, entertainment, and services. It seeks to invest in China focusing on Shenzhen, Shanghai, Beijing, Xi’an, and Wuhu. The firm also invests in Pearl River Delta region, Yangtze River Delta region, and Circum-Bohai-Sea region. For Pearl River Delta, it covers Guangzhou, Shenzhen, Foshan, Dongguan, Zhongshan, Zhuhai, Huizhou, Jiangmen, and Zhaoqing cities in China. For Yangtze River Delta, the firm covers Shanghai, Nanjing, Wuxi, Changzhou, Suzhou, Nantong, Yancheng, Yangzhou, Zhenjiang, Taizhou, Hangzhou, Ningbo, Jiaxing, Huzhou, Shaoxing, Jinhua, Zhoushan, Taizhou, Hefei, Wuhu, Ma’anshan, Tongling, Anqing, Chuzhou, Chizhou, and Xuancheng cities in China. For the Circum-Bohai-Sea region, it covers Beijing, Tianjin, Shenyang, Dalian, Qingdao, Dandong, Yingkou, Panjin, Fuxin, Huludao, Chaoyang, Shijiazhuang, Baoding, Tangshan, Qinhuangdao, Cangzhou, Langfang, Chengde, Zhangjiakou, Handan, Xingtai, Dongying, Yantai, Weifang, Weihai, Rizhao, and Binzhou cities in China. The firm prefers to invest 20% of its portfolio to early stage, 40% to expansion stage, and 40% to Pre-IPO stage. Shenzhen Oriental Fortune Capital Co Ltd. was formed in November 2007 and is based in Shenzhen, China with offices in Shanghai, China; Beijing, China; and Wuhu, China.
Show more...Investment focus
- Industry: Software, Information Technology, E-Commerce
- Stage:Series A, Series B, Seed
- Geography: China, United States
Investor stats
- Total investments: 166
- Round size: Seed $412k–$41M; Series A $1.4M–$27M; Series B $2.7M–$100M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — last raise in 2015
Portfolio highlights
- Microtreat — Microtreat specializes in the research, development, manufacturing, and sale of different high-end industrial application ultra-precision laser equipment, particularly equipment based on infrared, ultraviolet, green light, and ultra-short pulse technology, which is mostly utilized in the field of thin-film solar energy.
- Gene Cradle — Gene Cradle is a genetic company that develops gene therapy drugs to treat rare genetic diseases as well as chronic diseases.
- Pinfeng Medical — Pinfeng Medical is a platform firm that integrates independent research and development, manufacturing, marketing, and service to provide high-quality intelligent testing and precise diagnostic solutions to the local and international in vitro diagnostic industries.
ULTIMA is an investment management firm.
Show more...Investment focus
- Industry: Hardware, Software, Agriculture
- Stage:Angel, Series A
- Geography: China
Investor stats
- Total investments: 3
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Maimai — Maimai provides software and hardware smart care solutions for middle-to-high-end institutions, senior citizens, communities and home care.
- Mol Breeding — Mol Breeding is a biotech firm that focuses on animal and plants molecular breeding technology R&D and services.
Our team invests in early-stage digital health and consumer startups at CentreGold Capital.
Show more...Investment focus
- Industry: Internet, Medical Device, Artificial Intelligence
- Stage:Seed, Series A, Angel
- Geography: United States, China, Canada
Investor stats
- Total investments: 15
- Round size: Seed $549k–$3M; Series A $1.8M–$2.1M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — last raise in 2017
Portfolio highlights
- Fantuan — Order food with Fantuan Delivery. Get the best Asian food delivered to your door from your favorite local restaurants. Everyday promotion.
- IOT Pay — Omni Channel Payment Solution
- Saltalk — Saltalk is a virtual kitchen platform that focuses on Asian Authentic Food optimized for delivery services.
BOHE Angel Fund is an investment Fund.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Angel, Seed, Series A
- Geography: China
Investor stats
- Total investments: 7
- Lead/follow: no public data
Portfolio highlights
- Levostar — Levostar is a biotechnology company that specializes in the development and manufacture of cell and gene therapy products.
- Singlomics — Singlomics uses single-cell sequencing technology to develop antibody drugs for the treatment of infectious diseases and cancers.
- Shuimu BioSciences — Shuimu BioSciences Ltd. was founded in 2017 in Beijing, China, to bring the power of Cryo-EM to new therapeutics developers through a differentiated service offering, making the method accessible and affordable for Discovery teams at all stages of method adoption. We are the first commercial full service Cryo-EM platform in Asia, led by top expertsfrom Tsinghua University and experienced industry executives. All of our work is performed with the quality controls and service levels expected of a top tier contract research organization.
Orient Securities Capital Investment is an private equity fund business platform.
Show more...Investment focus
- Industry: Health Care, Manufacturing, Software
- Stage:Series A, Series D, Series C
- Geography: China
Investor stats
- Total investments: 26
- Round size: Series A $1.4M–$14M; Series D $49M–$69M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- HiStarlink — HiStarlink is a commercial company that makes communication technology like space-borne laser communication terminals and core devices. The main product matrix covers aerospace Advanced core optoelectronic devices, ultra-high-speed communication algorithms, laser communication terminals, and satellite-to-ground laser ground receiving systems.
- Shiyu Precision — Shiyu Precision is a high-tech enterprise specializing in the research, development and manufacture of semiconductor automation equipment.
- Soundcore Electronic Technology — Zhangjiagang Shengxin Electronic Technology Co., Ltd. is located in Huaxia Science and Technology Park, Zhangjiagang High-tech Industrial Development Zone. It was established on March 27, 2019 with a registered capital of 12 million yuan. It is an IDM enterprise integrating chip design, tape-out, packaging and testing. , with a complete industrialchain. The main products are: SAW RF chips and modules.
Lucion is an influential professional venture capital institute.
Show more...Investment focus
- Industry: Biotechnology, Medical, Manufacturing
- Stage:Series A, Seed, Series B
- Geography: China
Investor stats
- Total investments: 32
- Round size: Series A $1.4M–$522M; Series B $2.7M–$21M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- Best Ray — Bolui Laser is a high tech enterprises that focuses on independent research and development and industrialization of high-end lasers and laser applications. It offers clients h innovative solutions in the fields of industrial processing, cutting-edge scientific research, environmental monitoring, semiconductors, radar remote sensing, etc. andcompetitive products and advanced laser technology solutions to continue to create value for customers.
- Tage Zhixing — Beijing Tage Zhixing Technology Co., Ltd. is a high-tech enterprise focusing on mining vehicle unmanned driving technology research, product development, and overall engineering solution design and implementation of unmanned mines. Tage Zhixing has launched a car-ground-cloud collaborative smart mine unmanned transportation system, which realizescloud intelligent dispatching management, 4G.
- Xinhuan Technology — Xinhuan Technology specializes in advanced cardiovascular interventional, natural cavity imaging and advanced diagnostic procedures.
Sherpa Venture Capital is an investment firm that focuses on the investment and cultivation of the Pharmaceutical and Biotech industry. It also specializes in the investment and management of sector leaders and innovators within the Pharma, GeneTech, MedTech, Medical services, and various sub-sectors, where they have established robust portfoliosources, lasting value-adding cooperations and relationships, as well as mature all-cycle services with key resources. It was founded in 2018 and is headquartered in Beijing, China.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, Kenya
Investor stats
- Total investments: 64
- Round size: Series A $6.9M–$38M; Series B $14M–$74M; Series C $19M–$151M
- Lead/follow: 30% lead, 70% follow
- Last fund: Likely still investing — fund raised in 2021
Portfolio highlights
- New Vision Medical — New Vision Medical is an IT infrastructure service provider that offers clinical trial-related digital platforms and services.
- Leadsynbio — Pilot Bio is a bio-manufacturing technology research and development company, focusing on bio-manufacturing of major chemical products, bio-process substitution in heavy-polluting industries, etc., providing users with bio-catalytic synthesis processes, enzyme product research and development, production, sales, and downstream companies with enzymeengineering , Technical service outsourcing and production service outsourcing of strain transformation and metabolic engineering.
- Danking Pharmaceuticals — Danking Medicine is an innovation-driven drug developer.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 163
- Round size: Series A $11M–$69M; Series B $21M–$100M; Series C $27M–$275M
- Lead/follow: 26% lead, 74% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Akura Medical — Akura Medical is developing a next-generation thrombectomy device that aims to simplify thrombectomy through an easy-to-use, single-pass procedure that efficiently removes blood clots.
- Precede Biosciences — Precede Biosciences is revolutionizing precision medicine by revealing unprecedented insights into disease-defining biology from a simple blood test. Discover how we are helping create a world where medicine is developed more successfully, and every diagnosis is precise and minimally invasive.
- LYNK Pharmaceuticals — LYNK Pharmaceuticals is a biotech company focusing on the discovery and development of novel medicines to treat oncology, immunology, and inflammatory diseases. The company was founded in 2018 and is headquartered in Hangzhou, Zhejiang, China.
Med-Fine Capital is a venture capital firm focusing on early stage investments in China healthcare industry. The company is headquartered in Shanghai with offices in Beijing and Shenzhen.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Seed
- Geography: China, United States
Investor stats
- Total investments: 52
- Round size: Seed $8M–$21M; Series A $2.7M–$20M; Series B $11M–$50M
- Lead/follow: 37% lead, 63% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Med-Vision — Virtual reality (VR) medical care service provider based in Hangzhou.
- Degron Therapeutics — Degron Therapeutics is a leading platform company in discovery of molecular glue degraders for cancer treatment.
- Leadinno Medical Valley — Leadino Medical Valley is a producer of medical devices for neuroregulatory functions.
Green Pine Capital Partners is a venture capital firm.
Show more...Investment focus
- Industry: Artificial Intelligence, Manufacturing, Software
- Stage:Series A, Angel, Series B
- Geography: China, United States, Canada
Investor stats
- Total investments: 135
- Round size: Angel $412k–$2.1M; Series A $1.4M–$89M; Series B $9.6M–$150M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — raised $137M in 2019
Portfolio highlights
- Biodep — Biodep produces probiotics and derivatives, which are used in meals, healthy foods, cosmetics, environmental remediation, contemporary agriculture, and other industries.
- Readline — Readline is a biological immobilized enzyme catalysis technology application service provider.
- Guorui Xiechuang — Guorui Xiechuang is a joint venture subsidiary of Betterray New Materials Group Co., Ltd., provides power + energy storage products and system integration solutions for global customers.
CD Capital is a venture capital firm specialized in life sciences and medical technology. They are currently managing both RMB and USD funds with total size of $600M. CD Capital is operated by a professional team with diversified and profound industry backgrounds. They have made over 40 investments with high growth potential and earned a reputationas a premier venture capital firm with main focus on China healthcare industry. With broad network around China and the world, they have been able to seize the global trend, capture investment opportunities as well as help to define the future for China healthcare industry. Ultimately, they strive to grow best-in-class companies and deliver solid financial return to their investors.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Series B, Angel
- Geography: China, United States
Investor stats
- Total investments: 51
- Round size: Angel $412k–$14M; Series A $1.4M–$15M; Series B $6.9M–$34M
- Lead/follow: 41% lead, 59% follow
Portfolio highlights
- Kanova — Kanova is a biopharmaceutical firm.
- Acchrom Tech — Huapu Instrument (Beijing) Technology Co., Ltd. is committed to building Huapu into a well-known national brand in the field of chromatography, and is an enterprise that provides the overall solution of "product + technical service" in the field of chromatography. The company formulates differentiated marketing strategies, builds anationwide marketing team centered on key provinces, and builds a professional and efficient marketing network.
- Mol Breeding — Mol Breeding is a biotech firm that focuses on animal and plants molecular breeding technology R&D and services.
ASBV focuses on early and mid-term venture capital investments.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Seed, Angel
- Geography: China
Investor stats
- Total investments: 17
- Round size: Angel $412k–$412k; Series A $1.4M–$30M
- Lead/follow: 71% lead, 29% follow
Portfolio highlights
- Boundary Intelligent Control — Boundary Intelligent is specialized in creating airborne systems, such as flight control systems, that satisfy the needs of civil aircraft, as well as enhancing the ecology of the civil aviation industry and constructing aircraft perception, navigation, decision-making, and planning capabilities.
- Huasaiboman Medical Cell Biology — Warseeberman is a cell therapy solution provider, focusing on new cell therapy technologies, based on clinical research, and dedicated to the development of immune cell drug products for the treatment of solid tumors and stem cell therapy products for the treatment of degenerative diseases. The company aims at the cutting-edge technology of tumorimmunotherapy, focuses on the development of tumor infiltrating lymphocyte (TIL) drugs for solid tumors, and cooperates with many hospitals to establish a solid tumor and clinical transformation research institute, dedicated to bringing life to solid tumor patients Hope.
- Longyue Mechanical and Electrical Technology — Longyue Mechanical and Electrical Technology engaged in technologies, strengthened linkages, and provided commercial aircraft services.
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical.
Show more...Investment focus
- Industry: Biotechnology, Pharmaceutical, Health Care
- Stage:Series A, Series B, Series C
- Geography: United States, China, Israel
Investor stats
- Total investments: 42
- Round size: Series A $5.9M–$90M; Series B $6.8M–$100M; Series C $30M–$40M
- Lead/follow: 16% lead, 84% follow
- Last fund: May invest from a new fund soon — last raise in 2015
Portfolio highlights
- ShouTi — ShouTi specializes in the discovery and development of drugs against a type of targets called GPCR. The company develops drugs focused on novel small molecules for multiple unmet medical needs. ShouTi is currently operating in Stealth mode.
- Bioyond Tech — Bioyond Tech utilizes robotics and artificial intelligence technology to provide a new generation of modular products and automation solutions for the life sciences sector.
- Stemirna — Stemirna Therapeutics is a RNA technology based drug development company designed to maximize the potential of RNA science. The company currently has more than a dozen of independently-developed mRNA drug projects, focusing on the fields of mRNA-based personalized cancer vaccines, mRNA vaccines for infectious disease, protein defects diseases, andgenetic diseases, providing cure and solutions for cancer and infectious diseases, better serving patients.
Huimei Capital primarily seeks investment in the medical and healthcare ecosystem in a multi-dimensional and three-dimensional manner. It is committed to building a professional investment platform with international vision and local execution, helping early and growing medical and health companies to grow rapidly.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, Japan
Investor stats
- Total investments: 26
- Round size: Series A $10M–$220M; Series B $56M–$96M; Series C $30M–$69M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- Sensview — Sensview specializes in the development and production of solid-state imaging chips and detector modules.
- Bio-Engine — Bio-Engine is a developer of high-density serum-free suspension culture technology for animal cells. Its main products include HEK293 cell serum-free medium, PK15 cell serum-free medium, etc., which can be applied to antibodies, recombinant proteins, human and livestock. Virus vaccine, cell therapy and other fields.
- Zilixir Biotech — Zilixir Biotech develops a new protein design technology that offers possibilities for human exploration of the complex life sciences. SWORD™ protein design technology integrates binding pockets, new drug skeleton design, activity prediction, ADME/T prediction, etc., and has had some achievements in these areas, fully demonstrating theeffectiveness of protein design.
MiraclePlus invests in and accelerates early-stage startups. MiraclePlus assists startups in developing products that are good enough to succeed in the market. MiraclePlus' acceleration program works with the founders to get each team in top shape so that they can present to thousands of investors on Demo Day.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Information Technology
- Stage:Seed, Angel, Pre-Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 56
- Round size: Seed $200k–$3M; Angel $200k–$3M; Pre-Seed $300k–$2M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- YORG AI — Explore the future of work with YORG.AI
- Zhongke Jiahe — Zhongke Jiahe develops compilation technology and aspires to build a universal, low-cost, high-performance fundamental software tool chain.
- Light Wheel Intelligence — Light Wheel Intelligence is offers automated, physically precise and controllable, real and generalizable synthetic data solutions to build AI data infrastructure,
Step Fund is a chinese venture firm.
Show more...Investment focus
- Industry: Biotechnology, Software, Electronics
- Stage:Seed, Series B
- Geography: China
Investor stats
- Total investments: 3
- Lead/follow: no public data
Portfolio highlights
- Kiwimoore — Kiwimoore is a provider of advanced packaging chiplet technology for its customers. The company's intelligent integrated silicon substrate can connect homogeneous or heterogeneous chiplets with more flexibility, higher performance, and smaller size, and integrate to form a new system-on-chip, bringing new value to customers such as OEMs andfabless.
- Shanghai Bioprofile — Shanghai Bioprofile is a metabonomics technology service provider.
- YEASEN Biotechnology — YEASEN commitment to developing and producing high-quality enzyme products
Haitang Fund is a venture capital fund jointly established by Tianjin University alumni entrepreneurs and other alumni and entrepreneurs.
Show more...Investment focus
- Industry: Life Science, Biotechnology, Advanced Materials
- Stage:Series A
- Geography: China
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- Smart Cyano — Smart Cyano is a biotech company that integrates research and development, production, and sales of bioactive raw materials. It was established on August 27, 2018 and is headquartered in Qingdao, Fujian, China.
- Xingwei Technology — Xingwei Technology is a high-tech enterprise focusing on high-end equipment, develops and manufactures high-performance Machine equipment and motion control systems. .
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Ennovation Ventures is a venture capital firm that focuses on biomedical and medical health.
Show more...Investment focus
- Stage:Seed
- Geography: China
Investor stats
- Total investments: 5
- Lead/follow: no public data
Portfolio highlights
- Purui — Purui is a life big data service provider.
- Zenshine Pharma — Zenshine Pharma is a clinical-stage biopharmaceutical company with a focus on the development of small molecule drugs for cancer, viral infections, and autoimmune diseases.
- Human Zhizao — Human Intelligent Manufacturing is a fully automatic multiple flow fluorescence platform.
Saizhi Bole is an investment firm.
Show more...Investment focus
- Industry: Software, Manufacturing, Data and Analytics
- Stage:Series B
- Geography: China
Investor stats
- Total investments: 3
- Lead/follow: no public data
Portfolio highlights
- Derlead — Derlead is a biotechnology company that develops vitro diagnostic reagent products.
- Zhonghao Xinying — Zhonghao Xinying is an AI chip developer, mainly engaged in the research and development, design and sales of artificial intelligence core chips used in various cloud servers.
Wanwu Capital is an investment firm
Show more...Investment focus
- Industry: Artificial Intelligence, Agriculture, SaaS
- Stage:Series A, Seed
- Geography: China
Investor stats
- Total investments: 9
- Lead/follow: no public data
Portfolio highlights
- Mogic AI — Mogic AI is an advertising technology platform that provides tools to create and launch campaigns by pulling product images into ads using AI.
- Huida Tech — Heilongjiang Huida Technology Development Co., Ltd. is a developer of agricultural machinery operation detection equipment. It focuses on the combination of Internet technology and smart agriculture, and provides agricultural production efficiency and management level through information technology. It is a leading domestic agricultural machineryinformatization solution. provider.
- Mol Breeding — Mol Breeding is a biotech firm that focuses on animal and plants molecular breeding technology R&D and services.
Qingdao Qingchi Venture Capital is an investment firm.
Show more...Investment focus
- Industry: Biotechnology, Science and Engineering
- Stage:Series A
- Geography: China
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- Zilixir Biotech — Zilixir Biotech develops a new protein design technology that offers possibilities for human exploration of the complex life sciences. SWORD™ protein design technology integrates binding pockets, new drug skeleton design, activity prediction, ADME/T prediction, etc., and has had some achievements in these areas, fully demonstrating theeffectiveness of protein design.
- Philosopher's stone — Philosophers Stone focused on the biomaterials and regenerative medicine industries (Biomaterials & Regenerative Medicine), and it helps to develop a new generation of biomedical materials and tissue reconstruction products with the function of inducing regeneration, thereby providing an overall solution to the organ transplantation shortage.
Qiantang Venture Capital focuses on investment in domestic and overseas early-stage projects.
Show more...Investment focus
- Industry: Biotechnology, Science and Engineering
- Stage:Series A
- Geography: China
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Zilixir Biotech — Zilixir Biotech develops a new protein design technology that offers possibilities for human exploration of the complex life sciences. SWORD™ protein design technology integrates binding pockets, new drug skeleton design, activity prediction, ADME/T prediction, etc., and has had some achievements in these areas, fully demonstrating theeffectiveness of protein design.
ounded in 2016, SDIC Venture Capital Co., Ltd. (SDICVC) is a fund management company founded by the State Development and Investment Corp. (SDIC), under a market driven governance structure. SDICVC currently manages four funds, with total asset under management at RMB 14 Billion.SDICVC puts into practice the marketization and industrializationof the nation’s scientific and technological achievements, focusing on an investment strategy of "serving the national innovation strategy and focusing on the transformation of scientific and technological achievements". SDICVC puts its expertise and experience to work to achieve its goals of policy orientation and return on investment, faithfully implementing the national development strategy, striving to realize the synergy between the government, the society and the market, realizing its positioning as "an ideal, trustworthy, respected, influential partner” and its role as a leading professional venture fund management institution.
Show more...Investment focus
- Industry: Manufacturing, Biotechnology, Health Care
- Stage:Series B, Series A, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 84
- Round size: Series A $8.2M–$76M; Series B $2.7M–$275M; Series C $14M–$56M
- Lead/follow: 47% lead, 53% follow
- Last fund: May invest from a new fund soon — last raise in 2018
Portfolio highlights
- Yanming Biology — Pyrotech pharmaceuticals is a biotechnology company that focuses om development for drugs for the treatment of inflammation and tumors.
- Dehui Electronics — Dehui Electronics develops, manufactures, and sells high-performance electronic ceramics and related electronic components.
- Huaxun Semiconductor — Huaxun Semiconductor is a high-tech firm specialized in R&D, production, and distribution of essential materials for advanced integrated circuit packaging.The company focuses on providing system solutions and key materials for ultra-thin wafer processing and holding, ultra-thin device manufacturing, three-dimensional stack packaging, flexibledisplay, conductive interconnection, and other fields, guided by the lightness, thinness, and shortness of integrated circuits.
Hubei Tianchi Enterprise Management is engaged in corporate management services.
Show more...Investment focus
- Industry: Medical, Health Care, Life Science
- Stage:Series A
- Geography: China
Investor stats
- Total investments: 1
- Lead/follow: no public data
Portfolio highlights
- GENERAL BIOL — GENERAL BIOL is a biotechnology and life science service provider company.
Dynamic Balance Investment is a core subsidiary of Jiangning Technology Venture Capital , it focuses on investments in the biomedical, TMT, clean energy and new material industries.
Show more...Investment focus
- Industry: Health Care, Manufacturing, Biotechnology
- Stage:Series A, Angel, Seed
- Geography: China
Investor stats
- Total investments: 32
- Lead/follow: no public data
Portfolio highlights
- Sunpower Group — Sunpower Group is an enterprise driven by green investment, based and supported by manufacturing and engineering services, and driven by R&D and innovation. Sunpower Group is headquartered in Nanjing, Jiangning.
- Zhuoyi Zhineng — Zhuoyi Zhineng is a UAV system developer company.
- Changxiang Medical — Changxiang Medical is a brain disease and brain science product solution provider.
Qingdao Holdings International offers property leasing, production and sale of educational equipment, consulting services, real estate development, and loan financing.
Show more...Investment focus
- Industry: AgTech, Genetics, Life Science
- Stage:Seed
- Geography: China
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Changjin Biotechnology — Changjin Biotechnology engages in the research, development, and industrialization of microbial synthetic proteins.
Haoping Investment is an investment firm.
Show more...Investment focus
- Industry: Medical, Life Science, Biotechnology
- Stage:Seed
- Geography: China
Investor stats
- Total investments: 1
- Lead/follow: no public data
Portfolio highlights
- N1 Life — N1 Life is an innovative biomedical company that focused on drug discovery and development of PDC drugs in the anti-tumor pipeline.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Vulab Tech is an information security firm that provides security a vulnerability management and analysis solution through an AI engine.
Show more...Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Smart Cyano — Smart Cyano is a biotech company that integrates research and development, production, and sales of bioactive raw materials. It was established on August 27, 2018 and is headquartered in Qingdao, Fujian, China.
Kunlun Capital is a value-oriented and fundamentally driven family office. We do not manage external funds.
Show more...Investment focus
- Industry: Biotechnology, Medical, Genetics
- Stage:Seed, Series A, Series B
- Geography: China
Investor stats
- Total investments: 9
- Round size: Seed $20M–$27M
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- UniXell — UniXell develops cell therapies for the treatment of cancer and neurodegenerative disorders.
- Ningbo Shanshan — Ningbo Shanshan engaged in the research and development, manufacture and distribution of lithium battery materials.
- Zhongke Digital — ## Build Setup
CMS is a specialty pharmaceutical company based in China, focusing on marketing, promotion and sales of prescription drugs and other medicinal products to all therapeutic departments in hospitals nation-wide. CMS builds up its product portfolio for its target markets by asset acquisition, equity investment, licensing-in and distribution partnershipon the global basis as well as in-house R&D.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Seed
- Geography: China, United Kingdom
Investor stats
- Total investments: 2
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- N1 Life — N1 Life is an innovative biomedical company that focused on drug discovery and development of PDC drugs in the anti-tumor pipeline.
- Destiny Pharma — World-leading infection prevention.
Sunz Fund is a venture capital firm that focuses on investments in life science, medical health and resources environment sectors.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China
Investor stats
- Total investments: 12
- Round size: Seed $1.4M–$1.5M; Series A $1.4M–$1.4M; Series B $2.7M–$2.7M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- Treat Gut — Treat Gut provides a comprehensive solution for precise bacterial transplantation treatment.
- Yingsheng Biology — Yingsheng Biotechnology Co., Ltd. (referred to as Yingsheng Bio) was established in 2009, and is committed to the application of molecular diagnostic techniques such as maternal and child health, neonatal genetic diseases, metabolic diseases, birth defects and other human genetics, and national eugenics engineering. Yingsheng's product lineincludes 45 innovative genetic metabolic disease screening reagents, 14 vitamins determination reagents, mass spectrometer automatic intelligent processing platform, and ultra-high performance liquid chromatography tandem mass spectrometry detection system. level.
- AccuMed Technology — Shanghai AccuMed Technology Ltd. (R&D HQ) is an advanced medical technology development company who specializes in developing new technologies and manufacturing intelligent medical devices for precise surgical operation. The team consists of scientists and senior medical professionals to make this reality. The R&D HQ is located in theNeobay Global Innovation Base in Minhang District, Shanghai; and the manufacturing division (Nantong AccuMed Technology Ltd.) is located in Maipu Scientific Park in Chongchuan District, Nantong, Jiangsu. To support the development of minimally invasive and accurate clinical practices and fulfill the increasing clinical demand, AccuMed pays special attentions to develop a low-cost and highly-accurate surgical navigation system for total solutions on surgical and interventional therapy. AccuMed relies on the scientific research provided by the research lab of the School of Biomedical Engineering in Shanghai Jiao Tong University in order to maintain leading clinical advancements. Our world-leading research team can also perform seamless translational research. Relying on the matured and optimized business mode, we continue to contend for a better and more precise products.
Anhui High-tech Industry Investment is engaged in high-tech industry investment and related derivative business.
Show more...Investment focus
- Industry: Medical, Health Care, Life Science
- Stage:Angel
- Geography: China
Investor stats
- Total investments: 1
- Lead/follow: no public data
Portfolio highlights
- GENERAL BIOL — GENERAL BIOL is a biotechnology and life science service provider company.
Qiji Zhiguang Fund is an investment fund Of BGI.
Show more...Investment focus
- Industry: Life Science, Biotechnology
- Stage:Angel
- Geography: China
Investor stats
- Total investments: 1
- Lead/follow: no public data
Portfolio highlights
- Neurophth Therapeutics — Neurophth is China's first gene therapy company for ophthalmic diseases. As a clinical-stage company, Neurophth is dedicated to discovering and developing gene therapies for patients suffering from blindness and other eye diseases globally.
Tsing-Yuan Capital is a Chinese venture capital firm specialized in early, middle, and mature stage investments.
Show more...Investment focus
- Industry: Manufacturing, Health Care, E-Commerce
- Stage:Series A, Angel, Series B
- Geography: China, United States
Investor stats
- Total investments: 43
- Round size: Angel $412k–$412k; Series A $1.4M–$14M; Series B $2.7M–$14M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- Soundec — Soundec is an enterprise that focuses on acoustic research and commercialization. The company's products include modules containing software algorithms and audio processing chips, which are mainly used in wired digital headphones and Bluetooth wireless headphones.
- cheaptrustedpharmacy — 4B Technologies is a biotech company that develops novel medicines for neurodegenerative diseases and neurological injuries. Its drug development focuses on reliving pain symptoms from nervous system diseases such as stroke and glaucoma, enabling healthcare professionals to prescribe more effective treatments to their patients.The company wasfounded in 2017 and is based in Suzhou, China.
- Yishi Technology — Yishi Technology is a 3D vision laser sensor R&D manufacturer dedicated to the research and development of intelligent industrial cameras
Country Garden Ventures was established in January 2019. It is a first-level business unit of Country Garden Group. It is responsible for the group's equity investment business in addition to real estate investment. Since its establishment, Country Garden Ventures has always adhered to the investment strategy of “industry empowerment andvalue co-creation”, paying equal attention to financial investment and holding investment, and has initially formed a staged, dedicated track, and multi-level investment portfolio. Up to now, the team has accumulatively invested in many star companies such as Shell Search, Qinhuai Data, Ziguang Zhanrui, Penguin Almond, Hobo Pharmaceutical, Blue Arrow Aerospace, Xinruipeng Pet Medical, Lin Qingxuan and so on.
Show more...Investment focus
- Industry: Manufacturing, Biotechnology, Hardware
- Stage:Series A, Seed, Series B
- Geography: China, France, Germany
Investor stats
- Total investments: 18
- Round size: Series A $1.4M–$1.5B
- Lead/follow: 40% lead, 60% follow
Portfolio highlights
- HemaCell — Xueji Bio is a new cell therapy company founded by returnee experts to regenerate hematopoietic lineages (including blood cells and immune cells) in vitro, with unique stem cell reprogramming, editing and differentiation technologies. The company's unique iPSC establishment technology and gene targeting technology can quickly establish aplatform using platelet cells as a drug delivery carrier.
- Changjin Biotechnology — Changjin Biotechnology engages in the research, development, and industrialization of microbial synthetic proteins.
- China Resources Vanguard — China Resources Vanguard, doing business as China Resources Vanguard Shop or Vanguard, operates the supermarket chains of China Resources. It is the third-largest supermarket chain in Hong Kong. As of December 31, 2014, there are 4866 shops operating in Hong Kong and the mainland Chinese provinces/municipalities of Guangdong, Zhejiang,Jiangsu, Shanghai, Tianjin and Beijing.According to market research firm EuroMonitor's estimates in 2012, China Resources Vanguard supermarket market share in Hong Kong is about 7.8%. Wellcome Hong Kong's market share is about 39.8% and PARKnSHOP Hong Kong's market share is about 33.1%.On August 18, 2013, China Resources Enterprise's supermarket chain Vanguard and British supermarket Tesco signed a "memorandum of understanding", intending to set up a joint venture interest group in mainland China, Hong Kong and Macau, operating hypermarkets, supermarkets, convenience stores, liquor stores and cash and carry businesses. China Resources Enterprise took an 80% share and Tesco took a 20% share.
Starlight Capital provides investment and assistance to companies from the digital industry. It searches for businesses that are focusing on digital transformation and helps with its management. Starlight Capital is based in Shanghai, China.
Show more...Investment focus
- Industry: Software, Agriculture, Life Science
- Stage:Series A
- Geography: China
Investor stats
- Total investments: 2
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Mol Breeding — Mol Breeding is a biotech firm that focuses on animal and plants molecular breeding technology R&D and services.
- Yunna Technology — Yunna Technology is a provider of intelligent software technology products and services.
Cathay Biotech is a global technology leader in synthetic biology and the use of bio-processes to produce new materials on an industrial scale. Cathay’s long chain diacids are a perfect example demonstrating the potential for renewable bio-manufacturing to commercially displace traditional chemical processes. Cathay also developed and became thefirst commercial producer of pentanediamine from renewable materials. Having the two key monomers to produce polyamides, Cathay also is a global innovator in the commercialization of new and unique renewable polyamides for the engineering polymer and textile markets. As a game-changing production technology, bio-production starts with biomass and other raw materials for biological conversion to higher value products. The nature of bio-production requires environmentally friendly and mild conditions that are inherently economical. The goal of Cathay’s synthetic biology development programs is to address the excessive dependence of humans on traditionally produced chemicals as well as the subsequent environmental damage and worker safety issues associated with their production. Cathay’s headquarters and R&D are located within Zhangjiang Hi-Tech park in Shanghai, P.R. China and the two production sites are in Jinxiang, Shandong Province, and Wusu, Xinjiang Province, also in China.
Show more...Investment focus
- Industry: Medical, Life Science, Biotechnology
- Stage:Seed
- Geography: China
Investor stats
- Total investments: 1
- Lead/follow: 100% lead, 0% follow
Portfolio highlights
- MoleculeMind — MoleculeMind is an AI-integrated biotech firm that fuses artificial intelligence with biotechnology to form a new development platform.
Life Science Investor funding in China at a glance
Stats across 169 deals from 319 investors.
Access all 319 investors in China Life Science startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Life Science Investors in China investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 319 investors investing in China Life Science startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!